A Phase 3 interventional study of Romiplostim in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-14.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 13 in phase 3, and was the 8th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 407 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2005, is one of 10 in phase 3, and was the 8th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week. Dose adjustment will be based on platelet counts, and will be allowed throughout the duration of the study. Rescue therapies are allowed at any time during the study. Reductions in concurrent ITP therapies may occur at any time when platelet counts are > 50,000.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Romiplostim
Biological: Romiplostim
Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
Adverse Events
One or more occurences of one or more adverse events within the participant during the study. Participants with more than one event were only counted once
Time frame: Duration of Treatment plus 30 days or End of Study (whichever is later). Approximately 205 weeks.
Platelet Response (Definition 1)
Platelet response using definition1 . (a doubling of baseline platelet count and a platelet count of \>=50 x 10\^9/L
Time frame: Duration of treatment (up to 201 weeks)
Platelet Response (Definition 2)
Platelet response using definition 2 (a platelet count increase of \>=20 x 109/L from baseline)
Time frame: Duration of treatment (up to 201 weeks)
First Subject Enrolled: 24Feb2005 Last Subject Enrolled: 05Jan2010
| Milestone | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 |
|---|---|---|
| Started | 168 | 239 |
| Completed | 113 | 175 |
| Not completed | 55 | 64 |
| Withdrew: Adverse event | 6 | 10 |
| Withdrew: Death | 6 | 8 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 8 | 2 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 10 | 12 |
| Withdrew: Other | 11 | 2 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Requirement for alternative therapy | 7 | 15 |
| Withdrew: Protocol-specified criteria | 3 | 12 |
One or more occurences of one or more adverse events within the participant during the study. Participants with more than one event were only counted once
| participants | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 |
|---|---|---|
| Adverse Events | 162 | 215 |
Platelet response using definition1 . (a doubling of baseline platelet count and a platelet count of \>=50 x 10\^9/L
| Participants | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 |
|---|---|---|
| Platelet Response (Definition 1) | 156 | 214 |
Platelet response using definition 2 (a platelet count increase of \>=20 x 109/L from baseline)
| Participants | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 |
|---|---|---|
| Platelet Response (Definition 2) | 160 | 220 |
Collected over Average duration: cohort 1 52 wks; cohort 2 42 wks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romiplostim Cohort 1 | — | 61/168 (36.3%) | 155/168 (92.3%) |
| Romiplostim Cohort 2 | — | 61/239 (25.5%) | 188/239 (78.7%) |
| Event | Romiplostim Cohort 1 | Romiplostim Cohort 2 |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 10/168 | 10/239 |
| PneumoniaInfections and infestations | 6/168 | 3/239 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 5/168 | 2/239 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 5/168 | 0/239 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/168 | 3/239 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/168 | 1/239 |
| Urinary tract infectionInfections and infestations | 3/168 | 0/239 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 3/168 | 0/239 |
| PurpuraSkin and subcutaneous tissue disorders | 3/168 | 1/239 |
| Deep vein thrombosisVascular disorders | 3/168 | 1/239 |
| Event | Romiplostim Cohort 1 | Romiplostim Cohort 2 |
|---|---|---|
| HeadacheNervous system disorders | 57/168 | 61/239 |
| FatigueGeneral disorders | 50/168 | 25/239 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 46/168 | 34/239 |
| ContusionInjury, poisoning and procedural complications | 39/168 | 21/239 |
| NasopharyngitisInfections and infestations | 38/168 | 31/239 |
| CoughRespiratory, thoracic and mediastinal disorders | 35/168 | 22/239 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 34/168 | 31/239 |
| DiarrhoeaGastrointestinal disorders | 33/168 | 24/239 |
| NauseaGastrointestinal disorders | 32/168 | 38/239 |
| PetechiaeSkin and subcutaneous tissue disorders | 29/168 | 31/239 |
| Age, Continuous(years) | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 | Total |
|---|---|---|---|
| Mean | 53.6 ± 17 | 54.1 ± 18 | 53.9 ± 17.6 |
| Sex: Female, Male(Participants) | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 | Total |
|---|---|---|---|
| Female | 94 | 150 | 244 |
| Male | 74 | 89 | 163 |
| Race/Ethnicity, Customized(participants) | Romiplostim (AMG 531) Cohort 1 | Romiplostim (AMG 531) Cohort 2 | Total |
|---|---|---|---|
| White or Caucasian | 149 | 232 | 381 |
| Black or African American | 5 | 1 | 6 |
| Hispanic or Latino | 7 | 2 | 9 |
| Asian | 5 | 3 | 8 |
| Other | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
No study locations are listed for this record.
Ran from Feb 2005 to primary completion in Jan 2011, 71 months.
Results were first posted in Feb 2012, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 71 months is above that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →